Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated:  3/21/2018
Novartis Investigative Site
mi
from
North Hollywood, CA
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated: 3/21/2018
Novartis Investigative Site
mi
from
North Hollywood, CA
Click here to add this to my saved trials
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated:  3/21/2018
Novartis Investigative Site
mi
from
Atlantis, FL
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension
Status: Enrolling
Updated: 3/21/2018
Novartis Investigative Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
UC Davis Dept of Ophthalmology & Vision Science
mi
from
Sacramento, CA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
UC Davis Dept of Ophthalmology & Vision Science
mi
from
Sacramento, CA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Sall Medical Research Center
mi
from
Artesia, CA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Sall Medical Research Center
mi
from
Artesia, CA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Scripps Clinic at Torrey Pines
mi
from
La Jolla, CA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Scripps Clinic at Torrey Pines
mi
from
La Jolla, CA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Eye Research Foundation
mi
from
Newport Beach, CA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Eye Research Foundation
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Coastal Research Associates, LLC
mi
from
Atlanta, GA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Coastal Research Associates, LLC
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Clayton Eye Center
mi
from
Morrow, GA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Clayton Eye Center
mi
from
Morrow, GA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Ophthalmology Consultants Ltd
mi
from
Saint Louis, MO
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Ophthalmology Consultants Ltd
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
UNC Kittner Eye Center
mi
from
Chapel Hill, NC
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
UNC Kittner Eye Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Apex Eye
mi
from
Madeira, OH
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Apex Eye
mi
from
Madeira, OH
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Ophthalmology Associates
mi
from
Fort Worth, TX
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Ophthalmology Associates
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. DETECT (DEtection and Treatment of Early Cardiovascular Disease Trial)
Status: Enrolling
Updated:  3/23/2018
University of Minnesota, Variety Club Research Center 102
mi
from
Minneapolis, MN
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. DETECT (DEtection and Treatment of Early Cardiovascular Disease Trial)
Status: Enrolling
Updated: 3/23/2018
University of Minnesota, Variety Club Research Center 102
mi
from
Minneapolis, MN
Click here to add this to my saved trials
DASH Cloud: Using Digital Health to Improve Adherence to the DASH Diet Among Women
DASH Cloud: Using Digital Health to Improve Adherence to the DASH Diet Among Women at Risk for Cardiovascular Disease
Status: Enrolling
Updated:  3/27/2018
The Sarah W. Stedman Nutrition and Metabolism Center
mi
from
Durham, NC
DASH Cloud: Using Digital Health to Improve Adherence to the DASH Diet Among Women
DASH Cloud: Using Digital Health to Improve Adherence to the DASH Diet Among Women at Risk for Cardiovascular Disease
Status: Enrolling
Updated: 3/27/2018
The Sarah W. Stedman Nutrition and Metabolism Center
mi
from
Durham, NC
Click here to add this to my saved trials
Effect of Nitrate-rich Fruit and Vegetable Supplement on Blood Pressure
Nitrate-rich Fruit and Vegetable Supplement and Blood Pressure in Normotensive Healthy Young Males: a Randomized, Double-blinded, Placebo-controlled Trial
Status: Enrolling
Updated:  3/27/2018
Arizona State University
mi
from
Phoenix, AZ
Effect of Nitrate-rich Fruit and Vegetable Supplement on Blood Pressure
Nitrate-rich Fruit and Vegetable Supplement and Blood Pressure in Normotensive Healthy Young Males: a Randomized, Double-blinded, Placebo-controlled Trial
Status: Enrolling
Updated: 3/27/2018
Arizona State University
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops
A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost.
Status: Enrolling
Updated:  4/3/2018
Philadelphia Eye Associates
mi
from
Willingboro, NJ
Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops
A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost.
Status: Enrolling
Updated: 4/3/2018
Philadelphia Eye Associates
mi
from
Willingboro, NJ
Click here to add this to my saved trials
Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops
A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost.
Status: Enrolling
Updated:  4/3/2018
Philadelphia Eye Associates
mi
from
Philadelphia, PA
Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops
A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost.
Status: Enrolling
Updated: 4/3/2018
Philadelphia Eye Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ToRsemide for pOstpartum HYpertension
Torsemide for the Prevention of Persistent Postpartum Hypertension in Preeclamptic Women: A Randomized, Placebo-Control Trial
Status: Enrolling
Updated:  4/3/2018
University of Texas Health Science Center
mi
from
Houston, TX
ToRsemide for pOstpartum HYpertension
Torsemide for the Prevention of Persistent Postpartum Hypertension in Preeclamptic Women: A Randomized, Placebo-Control Trial
Status: Enrolling
Updated: 4/3/2018
University of Texas Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Status: Enrolling
Updated:  4/4/2018
University of Florida
mi
from
Gainesville, FL
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Status: Enrolling
Updated: 4/4/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Status: Enrolling
Updated:  4/4/2018
Emory University School of Medicine
mi
from
Atlanta, GA
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Status: Enrolling
Updated: 4/4/2018
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Status: Enrolling
Updated:  4/4/2018
Mayo Clinic, Division of Hypertension
mi
from
Rochester, MN
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Status: Enrolling
Updated: 4/4/2018
Mayo Clinic, Division of Hypertension
mi
from
Rochester, MN
Click here to add this to my saved trials
Age-Related Changes in Body Composition
Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors
Status: Enrolling
Updated:  4/4/2018
Johns Hopkins University
mi
from
Baltimore, MD
Age-Related Changes in Body Composition
Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors
Status: Enrolling
Updated: 4/4/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Age-Related Changes in Body Composition
Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors
Status: Enrolling
Updated:  4/4/2018
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Age-Related Changes in Body Composition
Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors
Status: Enrolling
Updated: 4/4/2018
National Institute of Aging, Clinical Research Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
Genetics of Hypertension Associated Treatments (GenHAT)
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment
Status: Enrolling
Updated:  4/4/2018
University of Kentucky
mi
from
Lexington, KY
Genetics of Hypertension Associated Treatments (GenHAT)
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment
Status: Enrolling
Updated: 4/4/2018
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
A Prospective, Randomized, Open-Label, 13 to 14-week Study of the Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Subjects With Left Ventricular Hypertrophy (LVH)
Status: Enrolling
Updated:  4/10/2018
Trinity Hypertension & Metabolic Research Institute
mi
from
Carrollton, TX
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
A Prospective, Randomized, Open-Label, 13 to 14-week Study of the Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Subjects With Left Ventricular Hypertrophy (LVH)
Status: Enrolling
Updated: 4/10/2018
Trinity Hypertension & Metabolic Research Institute
mi
from
Carrollton, TX
Click here to add this to my saved trials
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% Compared to Timolol Maleate Ophthalmic Solution, 0.5% in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated:  4/12/2018
Aerie Pharmaceuticals
mi
from
Bedminster, NJ
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% Compared to Timolol Maleate Ophthalmic Solution, 0.5% in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated: 4/12/2018
Aerie Pharmaceuticals
mi
from
Bedminster, NJ
Click here to add this to my saved trials
Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
Status: Enrolling
Updated:  4/19/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives
Status: Enrolling
Updated: 4/19/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated:  4/23/2018
UCSD Medical Center
mi
from
La Jolla, CA
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated: 4/23/2018
UCSD Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated:  4/23/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated: 4/23/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated:  4/23/2018
Tufts Medical Center
mi
from
Boston, MA
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated: 4/23/2018
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated:  4/23/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated: 4/23/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated:  4/23/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated: 4/23/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated:  4/23/2018
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Status: Enrolling
Updated: 4/23/2018
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated:  4/25/2018
Tulane University
mi
from
New Orleans, LA
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated: 4/25/2018
Tulane University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated:  4/25/2018
Regents of the University of Michigan
mi
from
Ann Arbor, MI
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated: 4/25/2018
Regents of the University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated:  4/25/2018
Univ of Rochester Medical Center
mi
from
Rochester, NY
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated: 4/25/2018
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated:  4/25/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated: 4/25/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated:  4/25/2018
Zhejiang University
mi
from
Hangzhou,
Chinese Older Adults-Collaboration in Health (COACH)Study
The Depression/Hypertension in Chinese Older Adults-Collaboration in Health
Status: Enrolling
Updated: 4/25/2018
Zhejiang University
mi
from
Hangzhou,
Click here to add this to my saved trials
Carvedilol PAH A Pilot Study of Efficacy and Safety
Beta Blockers in Pulmonary Arterial Hypertension (PAH) A Pilot Study of Efficacy and Safety
Status: Enrolling
Updated:  4/25/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Carvedilol PAH A Pilot Study of Efficacy and Safety
Beta Blockers in Pulmonary Arterial Hypertension (PAH) A Pilot Study of Efficacy and Safety
Status: Enrolling
Updated: 4/25/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Bogalusa Heart Study
Status: Enrolling
Updated:  4/25/2018
Tulane University
mi
from
New Orleans, LA
Bogalusa Heart Study
Status: Enrolling
Updated: 4/25/2018
Tulane University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
California Liver Research Institute
mi
from
Pasadena, CA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
California Liver Research Institute
mi
from
Pasadena, CA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
Inland Empire Liver Foundation
mi
from
Rialto, CA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Inland Empire Liver Foundation
mi
from
Rialto, CA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
Piedmont Atlanta Hospital
mi
from
Atlanta, GA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Piedmont Atlanta Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
Iowa Digestive Disease Center
mi
from
Clive, IA
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Iowa Digestive Disease Center
mi
from
Clive, IA
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
Digestive and Liver Disease Specialists; Mercy Medical Center
mi
from
Baltimore, MD
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Digestive and Liver Disease Specialists; Mercy Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
Gastro One
mi
from
Germantown, TN
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Gastro One
mi
from
Germantown, TN
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
Texas Clinical Research Institute
mi
from
Arlington, TX
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Texas Clinical Research Institute
mi
from
Arlington, TX
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
American Research Corporation at Texas Liver Institute
mi
from
San Antonio, TX
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
American Research Corporation at Texas Liver Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
IMIC
mi
from
Palmetto Bay, FL
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
IMIC
mi
from
Palmetto Bay, FL
Click here to add this to my saved trials
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated:  4/26/2018
Henry Ford Hospital
mi
from
Detroit, MI
Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
Status: Enrolling
Updated: 4/26/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials